Inducible Cre/loxP recombination in the mouse proximal tubule

Nephron - Experimental Nephrology

Volumn 106, Issue 1, 2007, Pages

  Dworniczak, Bernd ^a   Skryabin, Boris ^a   Tchinda, Joëlle ^a   Heuck, Silke ^a   Seesing, Franz Josef ^a   Metzger, Daniel ^b,c   Chambon, Pierre ^b,c   Horst, Jürgen ^a   Pennekamp, Petra ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b INSTITUT CLINIQUE DE LA SOURIS   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cre recombinase; Cre ERT2; Kidney; Tamoxifen

Indexed keywords

CRE RECOMBINASE; GAMMA GLUTAMYLTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE II; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC RECOMBINATION; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANIMALS; CELLS, CULTURED; INTEGRASES; KIDNEY TUBULES, PROXIMAL; MICE; MICE, TRANSGENIC; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TAMOXIFEN;

EID: 34247854919     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100554     Document Type: Article

References (40)

1. Branda CS, Dymecki SM: Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 2004;6:7-28.
2. Sauer B: Inducible gene targeting in mice using the Cre/lox system. Methods 1998;14:381-392.
3. Nagy A: Cre recombinase: the universal reagent for genome tailoring. Genesis 2000;26:99-109.
4. Igarashi P: Kidney-specific gene targeting. J Am Soc Nephrol 2004;15:2237-2239.
5. Lantinga-van Leeuwen IS, Leonhard WN, van de Wal A, Breuning MH, Verbeek S, de Heer E, Peters DJ: Transgenic mice expressing tamoxifen-inducible cre for somatic gene modification in renal epithelial cells. Genesis 2006;44:225-232.
6. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-5551.
7. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P: Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 1996;93:10887-10890.
8. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D: Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible cre-ER(T) and cre-ER(T2) recombinases. Nucleic Acids Res 1999;27:4324-4327.
9. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 1993;7:232-240.
10. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-1690.
11. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995;92:4206-4210.
12. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP: Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of cre recombinase. Curr Biol 1998;8:1323-1326.
13. Hayashi S, McMahon AP: Efficient recombination in diverse tissues by a tamoxifen-inducible form of cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002;244:305-318.
14. Feil R, Wagner J, Metzger D, Chambon P: Regulation of cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 1997;237:752-757.
15. Sepulveda AR, Huang SL, Lebovitz RM, Lieberman MW: A 346-base pair region of the mouse gamma-glutamyl transpeptidase type II promoter contains sufficient cis-acting elements for kidney-restricted expression in transgenic mice. J Biol Chem 1997;272:11959-11967.
16. Soriano P: Generalized lacZ expression with the ROSA26 cre reporter strain. Nat Genet 1999;21:70-71.
17. Le Y, Gagneten S, Larson T, Santha E, Dobi A, v Agoston D, Sauer B: Far-upstream elements are dispensable for tissue-specific proenkephalin expression using a cre-mediated knock-in strategy. J Neurochem 2003;84:689-697.
18. Ivanyi B, Olsen TS: Immunohistochemical identification of tubular segments in percutaneous renal biopsies. Histochemistry 1991;95:351-356.
19. Barresi G, Tuccari G, Arena F: Peanut and Lotus tetragonolobus binding sites in human kidney from congenital nephrotic syndrome of Finnish type. Histochemistry 1988;89:117-120.
20. Watanabe M, Muramatsu T, Shirane H, Ugai K: Discrete distribution of binding sites for Dolichos biflorus agglutinin (DBA) and for peanut agglutinin (PNA) in mouse organ tissues. J Histochem Cytochem 1981;29:779-780.
21. Rutenburg AM, Kim H, Fischbein JW, Hanker JS, Wasserkrug HL, Seligman AM: Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity. J Histochem Cytochem 1969;17:517-526.
22. Briere N, Martel M, Plante G, Petitclerc C: Heterogeneous distribution of alkaline phosphatase and gamma-glutamyl transpeptidase in the mouse nephron. Acta Histochem 1984;74:103-108.
23. Brake RL, Simmons PJ, Begley CG: Cross-contamination with tamoxifen induces transgene expression in non-exposed inducible transgenic mice. Genet Mol Res 2004;3:456-462.
24. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson C, Brent G, Zhou J: Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 mutation. Nat Genet 1997;17:179-181.
25. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000;97:1731-1736.
26. Pennekamp P, Karcher C, Fischer A, Schweickert A, Skryabin B, Horst J, Blum M, Dworniczak B: The ion channel polycystin-2 is required for left-right axis determination in mice. Curr Biol 2002;12:938-943.
27. Casanova E, Fehsenfeld S, Lemberger T, Shimshek DR, Sprengel R, Mantamadiotis T: ER-based double iCre fusion protein allows partial recombination in forebrain. Genesis 2002;34:208-214.
28. Leone DP, Genoud S, Atanasoski S, Grausenburger R, Berger P, Metzger D, Macklin WB, Chambon P, Suter U: Tamoxifen-inducible glia-specific cre mice for somatic mutagenesis in oligodendrocytes and Schwann cells. Mol Cell Neurosci 2003;22:430-440.
29. Tannour-Louet M, Porteu A, Vaulont S, Kahn A, Vasseur-Cognet M: A tamoxifen-inducible chimeric cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology 2002;35:1072-1081.
30. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
31. Vasioukhin V, Degenstein L, Wise B, Fuchs E: The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci USA 1999;96:8551-8556.
32. Guo C, Yang W, Lobe CG: A cre recombinase transgene with mosaic, widespread tamoxifen-inducible action. Genesis 2002;32:8-18.
33. Bugeon L, Danou A, Carpentier D, Langridge P, Syed N, Dallman MJ: Inducible gene silencing in podocytes: a new tool for studying glomerular function. J Am Soc Nephrol 2003;14:786-791.
34. Wen F, Cecena G, Munoz-Ritchie V, Fuchs E, Chambon P, Oshima RG: Expression of conditional cre recombinase in epithelial tissues of transgenic mice. Genesis 2003;35:100-106.
35. Zhao J, Nassar MA, Gavazzi I, Wood JN: Tamoxifen-inducible NaV1.8-CreERT2 recombinase activity in nociceptive neurons of dorsal root ganglia. Genesis 2006;44:364-371.
36. Venkatachalam MA, Bernard DB, Donohoe JF, Levinsky NG: Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments. Kidney Int 1978;14:31-49.
37. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ: ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci USA 1998;95:8075-8080.
38. Farquhar MG, Saito A, Kerjaschki D, Orlando RA: The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995;6:35-47.
39. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, Herz J: Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci USA 1996;93:8460-8464.
40. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999;155:1361-1370.